» Articles » PMID: 17923611

Baseline Predictors of Rates of Hippocampal Atrophy in Mild Cognitive Impairment

Overview
Journal Neurology
Specialty Neurology
Date 2007 Oct 10
PMID 17923611
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A large cohort of subjects with mild cognitive impairment (MCI) was categorized into tertiles based on hippocampal atrophy rates, as a proxy for Alzheimer-type pathology. We compared baseline clinical, neuropsychological, and MRI measures to characterize these MCI subgroups.

Methods: Serial MRI data of 323 subjects with MCI (49% men; mean +/- SD age: 69 +/- 9 years), followed for 2 years in a clinical trial, were available. Baseline hippocampal and whole brain volumes (WBV) were measured, and hippocampal volume change was assessed. Baseline medial temporal lobe atrophy (MTA), white matter hyperintensities (WMH), and lacunes were rated visually. The cohort was categorized into tertiles based on hippocampal atrophy rates (absent, moderate, and severe).

Results: Rates of hippocampal atrophy (%/year) were 0.0 +/- 0.8 in the absent, 1.7 +/- 0.4 in the moderate, and 3.6 +/- 1.0 in the severe (mean +/- SD) tertile. Older age and the APOE epsilon 4 allele were associated with higher hippocampal atrophy rates (p < 0.0001 and p = 0.015). General cognition deteriorated over the MCI groups (p < 0.0001), whereas, after adjustment for age and sex, episodic memory and executive function did not. Baseline hippocampal atrophy was associated with increasing atrophy rates (hippocampal volume: p = 0.025; MTA score: p = 0.008); in contrast, WBV, WMH, and lacunes, adjusted for age and sex, were not significantly associated with hippocampal atrophy rates.

Conclusions: In mild cognitive impairment (MCI), older age, poorer general cognition, hippocampal atrophy, and APOE epsilon 4 predict subsequent accelerated rates of hippocampal atrophy, suggestive of the accumulation of Alzheimer-type pathology, which may become clinically manifest in the future. These markers may improve identification of subjects with MCI at risk for Alzheimer disease.

Citing Articles

Precision Estimates of Longitudinal Brain Aging Capture Unexpected Individual Differences in One Year.

Elliott M, Du J, Nielsen J, Hanford L, Kivisakk P, Arnold S medRxiv. 2025; .

PMID: 40061349 PMC: 11888524. DOI: 10.1101/2025.02.21.25322553.


Associations of screen-based sedentary activities with all cause dementia, Alzheimer's disease, vascular dementia: a longitudinal study based on 462,524 participants from the UK Biobank.

Yuan S, Li W, Ling Y, Huang X, Feng A, Tan S BMC Public Health. 2023; 23(1):2141.

PMID: 37919716 PMC: 10621115. DOI: 10.1186/s12889-023-17050-3.


Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele.

Ji X, Peng X, Tang H, Pan H, Wang W, Wu J Brain Pathol. 2023; 34(1):e13208.

PMID: 37646624 PMC: 10711266. DOI: 10.1111/bpa.13208.


Comprehensive analysis of the expression and prognosis for APOE in malignancies: A pan-cancer analysis.

Yu S, Qian L, Ma J Oncol Res. 2023; 30(1):13-22.

PMID: 37304007 PMC: 10207989. DOI: 10.32604/or.2022.026141.


N-acetyl-aspartate and Myo-inositol as Markers of White Matter Microstructural Organization in Mild Cognitive Impairment: Evidence from a DTI-H-MRS Pilot Study.

Valatkeviciene K, Levin O, Sarkinaite M, Vints W, Kunickaite R, Danyle G Diagnostics (Basel). 2023; 13(4).

PMID: 36832141 PMC: 9955118. DOI: 10.3390/diagnostics13040654.